SkinBioTherapeutics has announced its acquisition of Bio-Tech Solutions, marking its second major purchase.
- The acquisition was facilitated with financial support from key shareholders and internal reserves.
- Bio-Tech Solutions, based in Yorkshire, is known for health and hygiene product manufacturing.
- This strategic move aims to provide operational synergies and expand SkinBioTherapeutics’ product line.
- Company leadership emphasises the acquisition as crucial to its growth and transformation plans.
SkinBioTherapeutics, a life sciences company based in Newcastle, has successfully acquired Bio-Tech Solutions Ltd (BTS) in Yorkshire for £1.25 million. This significant acquisition was financed through a combination of a three-year loan from a key shareholder, David Brierwood, a fundraise of £250,000, along with the utilisation of group financial reserves.
BTS is a reputable manufacturer specialising in health, hygiene, and personal care products, employing 23 professionals across various departments, including manufacturing, packaging, formulation, and regulatory affairs. For the fiscal year ending June 30, the company reported a revenue of £2.1 million and an EBITDA of approximately £500,000, with expectations for continued growth.
This acquisition by SkinBioTherapeutics, which follows its purchase of Dermatonics Limited in January, is expected to realise cost synergies while paving the way for a platform to develop advanced topical treatments and capsules. Additionally, the company now enjoys a secure financial runway, enabling continuous operations until mid-2026.
Stuart Ashman, CEO of SkinBioTherapeutics, stated, “This is the second acquisition we have made as part of our buy and build strategy to generate immediate and longer-term benefits to the SkinBioTherapeutics Group.” He noted the strategic benefits in terms of revenue, EBITDA, and cost efficiencies while integrating an extensive customer base in the healthcare sector.
Ashman further elaborated that the acquisition ensures access to regulatory-approved manufacturing facilities, which are pivotal for the group’s product portfolio expansion. This move not only supports the company’s existing operations but also strengthens long-term business pillars. “These two acquisitions provide us with a strong product portfolio and integrated manufacturing,” Ashman added, underscoring the transformation underway within the business.
Meanwhile, BTS founder Ian Moulds expressed confidence in the transition: “Building up BTS has been a life’s work. As I reach retirement, I’m very happy to be handing it over to the SkinBioTherapeutics team.” Moulds praised the extensive due diligence and voiced his strong support for SkinBioTherapeutics’ expansion plans in the skin and personal healthcare markets.
The acquisition of BTS marks a significant milestone in SkinBioTherapeutics’ strategic growth and transformation journey.
